Use of biomarker testing in lung cancer among Puerto Rico and Florida Physicians: Results of a comparative study

scientific article published on 01 October 2019

Use of biomarker testing in lung cancer among Puerto Rico and Florida Physicians: Results of a comparative study is …
instance of (P31):
scholarly articleQ13442814

External links are
P932PMC publication ID6953751
P698PubMed publication ID31930172

P50authorGwendolyn P QuinnQ57056453
P2093author name stringSteven K Sutton
Teresita Muñoz-Antonia
Vani N Simmons
Matthew B Schabath
Alberto Chiappori
Iffat Alam
P2860cites workBiomarkers of Exposure among U.S. Adult Cigar Smokers: Population Assessment of Tobacco and Health (PATH) Study Wave 1 (2013-2014)Q64130688
National survey of perspectives of palliative radiation therapy: role, barriers, and needsQ80257929
NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 5.2018Q90101749
Somatic mutations affect key pathways in lung adenocarcinomaQ24648102
Gene aberrations for precision medicine against lung adenocarcinomaQ26749348
Screening for epidermal growth factor receptor mutations in lung cancerQ29619696
Spectrum of LKB1, EGFR, and KRAS mutations in chinese lung adenocarcinomasQ33563803
Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for MolecularQ34159011
Getting physicians to respond: the impact of incentive type and timing on physician survey response ratesQ34554717
Frequency of EGFR mutations in 907 lung adenocarcioma patients of Indian ethnicityQ35016912
Lung cancer mutations and use of targeted agents in HispanicsQ35636924
Why are response rates in clinician surveys declining?Q35886455
Frequency of EGFR and KRAS mutations in lung adenocarcinomas in African AmericansQ35915133
EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII).Q36250691
Personalized medicine and access to health care: potential for inequitable access?Q36543050
Racial and Ethnic Differences in the Epidemiology and Genomics of Lung Cancer.Q37684483
Physicians' attitudes about multiplex tumor genomic testingQ37712065
EGFR mutation testing in lung cancer: a review of available methods and their use for analysis of tumour tissue and cytology samplesQ38061599
Non-Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in OncologyQ40244899
Genotyping non-small cell lung cancer (NSCLC) in Latin AmericaQ43484361
Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinibQ46618741
Underutilization and disparities in access to EGFR testing among Medicare patients with lung cancer from 2010 - 2013.Q52648399
EGFR mutation frequency in Middle East and African non-small cell lung cancer patients: a systematic review and meta-analysisQ58741684
P433issue8
P921main subjectbiomarkerQ864574
P304page(s)33-40
P577publication date2019-10-01
P1476titleUse of biomarker testing in lung cancer among Puerto Rico and Florida Physicians: Results of a comparative study
P478volume5